The results demonstrated that PGRMC1 expression is associated with a higher risk of early relapse (within 5 years) across all patients with breast cancer [HR = 1.25; 95% confidence interval (CI) = 1.12–1.39; P = 6.4 × 10−5; Fig. 2A]. This evidence concerns the gene PGRMC1 and breast carcinoma.